Clinical Research Papers:
Meta-analysis comparing maintenance strategies with continuous therapy and complete chemotherapy-free interval strategies in the treatment of metastatic colorectal cancer
Metrics: PDF 2724 views | HTML 2323 views | ?
Lei Zhao1, Jing Wang1, Huihui Li1, Juanjuan Che1, Bangwei Cao1
1Department of Oncology, Beijing Friendship Hospital, Capital Medical University, Beijing, China
Bangwei Cao, email: [email protected]
Keywords: randomized controlled trials, grade 3 to 4 toxicities, pooled analysis, systematic review, optimal maintenance strategies
Received: September 01, 2015 Accepted: March 26, 2016 Published: April 08, 2016
There is as yet no consensus as to the best choice among the three treatment options (maintenance, complete chemotherapy-free intervals [CFIs], and continuous) for metastatic colorectal cancer (CRC). We performed a meta-analysis of six trials (N = 2, 454 patients) to compare the safety and efficacy of those three treatment strategies. Maintenance appeared to offer an advantage over CFI with respect to progression-free survival (PFS) (hazard ratio [HR]: 0.53, 95% confidence interval [CI], 0.40–0.69). PFS and overall survival (OS) were comparable between the maintenance and continuous strategies (HR: 1.18, 95% CI, 0.96–1.46; HR: 1.05, 95% CI, 0.98–1.27, respectively), as was OS between the maintenance and CFI strategies (HR: 0.84; 95% CI, 0.70–1.00). The incidence of grade 3/4 toxicity, including neutropenia, neuropathy, hand-foot syndrome and fatigue, was lower with maintenance than with continuous therapy. A maintenance regimen utilizing bevacizumab-based doublets appeared to confer a slight advantage over bevacizumab monotherapy with respect to PFS (P = 0.011). Maintenance appeared to reduce cumulative grade 3/4 toxicity as compared to the continuous strategy, while showing comparable efficacy. Bevacizumab-based doublets appeared to be of particular value in patients with metastatic CRC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.